Equol (Isoflavone Metabolite · ERβ-selective · Menopausal · Bone Density)

Compound	S-Equol ((S)-4′,7-Isoflavanediol; (3S)-3-(4-Hydroxyphenyl)-7-chroman-ol)
Chemical class	Polyphenol — Isoflavanediol (gut microbial metabolite; daidzein fully reduced; non-isoflavone isoflavandiol scaffold)
CAS	531-95-3
Primary source	Gut microbial metabolite of daidzein — produced by Lactonifactor longoviformis, Slackia isoflavoniconvertens; not a direct plant constituent
Key applications	Phytoestrogenic (most potent dietary; ERβ-selective); menopausal hot flush; bone density; cardiovascular
Claim strength	Moderate to High
Typical form	Racemic equol supplement; S-equol supplement (Equelle®/Prevera®); soy/red clover isoflavone as substrate for in vivo equol production
Buy from Herbuno	Availability on request — request bulk pricing →

Name origin: Equol was first isolated in 1932 from pregnant mare urine — "equol" from "equus" (horse). Its plant origin was not recognised until the 1980s when it was identified as a gut microbial metabolite of soy isoflavones. Equol is an isoflavanediol — the fully reduced form of daidzein (both C2-C3 and C3-C4 double bonds reduced), placing it in a unique chemical sub-class distinct from isoflavones. The pharmacologically relevant form is S-equol (the natural enantiomer produced by gut bacteria). Traditional use: Equol is not a plant constituent and has no direct traditional medicinal use. Its biological significance was recognised through the observation that Japanese and Asian populations with high soy intake had lower menopausal symptom rates and breast cancer incidence — epidemiological associations that led to isoflavone research and ultimately to the discovery that equol-producing individuals drove these associations. Research trajectory: Equol is the most potent known dietary phytoestrogen — with higher ERβ binding affinity than genistein, daidzein, or any intact plant isoflavone. The equol production divide (equol producers ~30–60% Western, ~50–80% Asian populations) is now recognised as the primary variable explaining inconsistent isoflavone clinical trial results. Commercial S-equol supplements (Equelle® in Japan/US, Prevera® in Europe) were developed specifically for equol non-producers. Commercial source: Commercial equol isolate is not currently available in the Herbuno catalogue at product-specific level; availability on request. Soy Isoflavones 80% (daidzein as substrate) is the precursor delivery approach for equol producers.

---

Evidence for Equol Applications

Menopausal hot flush reduction: Multiple RCTs with S-equol supplementation (10 mg twice daily = 20 mg/day) demonstrate significant hot flush frequency reduction (25–50% vs. placebo) in post-menopausal women who are equol non-producers — the target population for equol supplements. The Equelle® Phase III RCT in Japan (Aso et al. 2012, Menopause) and subsequent studies confirm the hot flush efficacy. A meta-analysis of equol-related soy studies (Lethaby et al. 2013 (Cochrane)) found that equol-producer subgroups showed significantly greater menopausal symptom improvement than non-producers. Claim strength: Moderate to High.

Bone density: S-equol stimulates osteoblast differentiation (RUNX2 upregulation) and inhibits osteoclastogenesis (RANKL/OPG modulation) via ERβ-mediated signalling. In post-menopausal rodent models, S-equol supplementation preserves bone mineral density with potency approaching low-dose oestrogen. Human studies show bone marker improvement (reduced NTx urinary excretion, improved osteocalcin) in equol supplemented post-menopausal women. The strongest bone density human data derive from equol producer subgroup analyses in soy isoflavone trials. Claim strength: Moderate.

Cardiovascular: S-equol improves endothelial function (flow-mediated dilation) and reduces LDL oxidation in post-menopausal women in small RCTs. ERβ-mediated eNOS activation in vascular endothelium and smooth muscle relaxation contribute to blood pressure modulation. Claim strength: Moderate.

ERβ mechanism — tissue selectivity advantage: S-equol's ERβ selectivity over ERα (approximately 5:1 ERβ:ERα selectivity) is pharmacologically advantageous — ERβ agonism provides bone, cardiovascular, and neurological benefits while avoiding ERα-mediated stimulation of breast and uterine tissue growth. This selectivity positions equol more favourably than non-selective phytoestrogens for long-term use in oestrogen-sensitive contexts. Claim strength: Moderate (mechanistic basis for safety profile).

---

Dosage & Formulator Specification

Commercial S-equol supplement RCTs (Equelle®) have used 10 mg twice daily (20 mg/day total S-equol) for menopausal hot flush reduction — with effects comparable to low-dose soy isoflavone preparations but with more consistent response across individuals regardless of gut microbiome composition. This is the evidence-based dose for equol supplementation in equol non-producers. Lower doses (5–10 mg/day) have been used in bone density studies.

S-equol is produced commercially by fermentation of soy isoflavones with equol-producing bacterial cultures (primarily Lactococcus strain 20-92) — yielding racemic or enriched S-equol preparations. The S-enantiomer is the biologically active form (R-equol has much lower ERβ affinity). Equol supplements should specify S-equol content, not racemic equol, for clinical relevance. S-equol is available from Japanese supplement manufacturers (ACS/Otsuka) who supply the Equelle® formulation.

For formulators seeking a pragmatic approach: providing daidzein substrate (Soy Isoflavones 80% — 40 mg/day total isoflavones including ~12 mg daidzein) combined with probiotic strains supporting equol production (Lactobacillus acidophilus, Bifidobacterium longum with beta-glucosidase activity) represents a prebiotic-enhanced strategy. However, equol production is not guaranteed regardless of substrate provision — gut microbiome composition remains the primary variable. Commercial S-equol supplementation is the more direct approach for equol non-producers.

S-equol safety: no significant adverse events reported in multiple RCTs up to 12 months at 20 mg/day. The ERβ selectivity supports a safer profile than non-selective phytoestrogens for long-term use, though ER-positive breast cancer precaution applies until larger long-term safety data accumulate. No thyroid interaction has been documented for equol (unlike some parent isoflavones).

---

Frequently Asked Questions — Equol

Am I an equol producer and how can I find out?
Equol producer status is determined by urine or blood equol measurement after a standardised soy isoflavone challenge (typically 50 mg soy isoflavones consumed, urine collected at 8–24 hours). Commercial urine equol test kits are available from clinical laboratories. Approximately 30–60% of Western adults and 50–80% of Asian adults are equol producers — the difference attributed to dietary history (high fibre, fermented food intake), antibiotic use history, and geographic gut microbiome variation. Equol producer status is relatively stable in adults but can be modified by probiotic and prebiotic interventions.

Why is equol more potent than genistein if it comes from a plant isoflavone?
Equol's structural reduction (fully saturated C-ring) from daidzein produces an isoflavanediol scaffold that fits ERβ's ligand binding domain with higher complementarity than the isoflavone scaffold. The C-ring saturation in equol removes aromatic ring planarity, allowing more flexible 3D conformational fitting to the ERβ binding pocket. Equol's Ki for ERβ is approximately 0.2–0.4 nM — similar to oestradiol's ERβ affinity — while genistein's Ki is approximately 0.5–1 nM. The small numerical difference belies a substantial pharmacological impact, as equol's higher systemic bioavailability and longer half-life amplify the effective potency difference.

Should equol non-producers take daidzein or direct equol supplements?
For confirmed equol non-producers, direct S-equol supplementation (20 mg/day) provides the most reliable phytoestrogenic response. Daidzein supplementation in non-producers delivers daidzein's own modest phytoestrogenic activity (significantly weaker than equol) without the equol conversion benefit. Probiotic-enhanced daidzein supplementation may convert some non-producers to partial producers over time, but efficiency is variable and not guaranteed. The most evidence-based approach for equol non-producers seeking the full phytoestrogenic benefit is S-equol supplement, not isoflavone precursor.

Is equol available as a standalone supplement ingredient in India?
Commercial S-equol as a supplement ingredient is primarily manufactured in Japan (ACS/Otsuka Pharmaceutical) and is not yet widely available from Indian botanical ingredient suppliers. As a fermentation-derived compound (not a direct botanical extract), equol's supply chain differs from standard plant extract ingredients. Herbuno is currently exploring availability; contact via the quotation page for the latest sourcing status. The soy isoflavone substrates (Soy Isoflavones 80% delivering daidzein) are readily available from Herbuno as an alternative approach.

Related compounds: Daidzein, Daidzin, Genistein, Formononetin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery